Muhammad Bilal Abid, MD, MRCP, assistant professor of medicine in the Divisions of Hematology/Oncology and Infectious Diseases at the Medical College of Wisconsin, discusses challenges with CAR-T cell therapy during the coronavirus disease 2019 (COVID-19) pandemic.

COVID-19 has caused many disruptions in the administration of CAR T-cell therapy​, says Abid. As such, several considerations need to be taken into account.

To mitigate the risk of severe cytokine release syndrome, ​CAR T-cell therapy should be brought to a temporary halt​, Abid explains. Doing so will prevent dysfunctional T cells and an elevation of inflammatory cytokines.

After stopping CAR T-cell therapy, it is critical to closely monitor patients, Abid concludes.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

CAR T-cell Therapy

 CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment. 

Muhammad Bilal Abid, MD, MRCP, discusses challenges with CAR-T cell therapy during the coronavirus disease 2019 pandemic.

Dr. Abid on Challenges With CAR T-Cell Therapy During the COVID-19 Pandemic